Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.
Kidney Int
; 105(3): 442-444, 2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38388145
ABSTRACT
This commentary provides an analysis of the study by Fu et al. in Kidney International, which employs 3 administrative databases to investigate the hyperkalemia protective effects of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors. It emphasizes the methodological approach, notably the use of a fixed-effect model to aggregate pairwise comparisons from 3 data sets. In addition, we explored the broader cardiorenal and potential nonrenal benefits of these drug classes, underscoring the imperative for continued research in this domain.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Diabetes Mellitus Tipo 2
/
Inhibidores de la Dipeptidil-Peptidasa IV
/
Inhibidores del Cotransportador de Sodio-Glucosa 2
Límite:
Humans
Idioma:
En
Revista:
Kidney Int
Año:
2024
Tipo del documento:
Article
País de afiliación:
Taiwán